Synectics Regulatory News (SNX)

18 Sep 2006 09:11

Synexus Clinical Research PLC18 September 2006 Synexus Clinical Research plc appointsPaul McCluskey as Chief Financial Officer Synexus Clinical Research plc ("Synexus") the international organisationproviding patient recruitment to the global clinical trials industry, is pleasedto announce the appointment of Paul McCluskey as Chief Financial Officer withimmediate effect. Most recently, Paul, aged 42, was the European Managing Director of the formerlyautonomous subsidiary of RHM plc, RHM Ingredients Ltd, which was acquired byprivate American owners. He is a fellow of the Institute of CharteredAccountants and previously held finance positions with BAE Systems plc andGlaxoSmithKline plc. Paul succeeds Chris Neilson, the previous Finance Directorof Synexus, who is leaving the company to pursue other opportunities. The boardwould like to thank Chris and wish him well for the future. Michael Fort, CEO of Synexus, commented "We are delighted to have attracted Paul to Synexus. He has considerableexperience of managing acquisitions and integrating those operations into aunified business. Synexus' strategy is to build, through targeted acquisitions,an international patient recruitment capability to manage large numbers ofclinical trial patients for pharmaceutical clients. Paul's experience inintegrating businesses, systems and management teams will strengthen our overallcapabilities as we continue to expand." The following information is given in respect of Paul McCluskey as required bySchedule 2 paragraph (g) of the AIM Rules. Directorships held within the previous five years Newly Weds Foods (Europe) Limited Newly Weds Foods Limited NWF Europe Limited RHM Ingredients Limted Press enquiries:Synexus Clinical Research plc Tel: +44 (0)1257 230 723Michael Fort, Chief ExecutiveBiddicks - Financial Public Relations Tel: +44 (0)20 7448 1000Zoe Biddick This information is provided by RNS The company news service from the London Stock Exchange